Title

Biomarkers for amyotrophic lateral sclerosis

Document Type

Article

Abstract

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease. ALS is a fatal neurodegenerative disease and clinical diagnosis typically takes many months to complete. Early disease diagnosis through the use of biomarkers may aid in correct clinical management of patients and possibly delay time to ventilator and morbidity. This review explores the progress of biomarker discovery efforts for ALS and the many challenges that remain. Included are different technologies utilized in biomarker discovery efforts (proteomic, genomic and metabolomic) and putative biomarkers uncovered using these techniques. These studies have discovered genetic mutations leading to familial forms of ALS, and specific protein alterations that occur in biological fluids (cerebrospinal fluid and blood) and/or tissues of ALS subjects. More recent high-throughput technologies have revealed panels of proteomic or metabolic biomarkers that can discriminate between ALS and control groups. The identification of disease-specific biomarkers will provide opportunities to develop early diagnostic measures as well as surrogate markers to monitor disease progression and test drug efficacy in clinical trials. © 2006 Future Drugs Ltd.

Publication Date

8-10-2006

Publication Title

Expert Review of Molecular Diagnostics

ISSN

14737159

E-ISSN

17448352

Volume

6

Issue

3

First Page

387

Last Page

398

PubMed ID

16706741

Digital Object Identifier (DOI)

10.1586/14737159.6.3.387

This document is currently not available here.

Share

COinS